

Pharmacy and Therapeutics Committee Meeting  
December 2, 2003  
Kellogg Hotel and Conference Center

Draft Minutes

**Committee Members in Attendance**

David Johnson, M.D., chairman  
Robert Coffey, PharmD  
Debera Eggleston, M.D.  
Robert Ernst, M.D.  
Jonathan Henry, M.D.  
Giovanino Perri, M.D.  
Max Robins, D.O.

**Committee Member Not in Attendance**

Edward Keating, RPh

**Representatives of the Department of Community Health in Attendance**

Paul Reinhart, Director, Medical Services Administration  
Susan Moran, Director, Bureau of Medicaid Program Operations  
George Baker, M.D., Chief Medical Consultant, Children's Special Health Care Services  
Mary Sandusky, RPh, Pharmacy Consultant  
Bradley Sprecher, Pharmacy Section Analyst

**Representatives of First Health Services Corporation in Attendance**

Annette Paul, RPh, Clinical Manager, Michigan Medicaid  
Luenetta Jackson, PharmD, Michigan Account Manager

**Public Audience**

Approximately 60 persons attended.

## Proceedings

- I. Dr. David Johnson opened the meeting at 6:10 p.m.
- II. Dr. Johnson welcomed and introduced participants from DCH and First Health. He also provided guidelines for public comment.
- III. Dr. Johnson mediated the Public Comment period. Speakers are listed in the order of presentation:
  - James Dube, Purdue Pharma: Spectracef
  - Rick Detloff, Pfizer: Relpax and Xalatan
  - Steven Stryk, GSK: Flonase
  - Tom Katofiasc, Specialized Pharmacy: Prevacid Solutab
  - Curt Griffith, TAP: Prevacid Solutab
  - Terry Whiteman, M.D., Lansing, MI, King Pharmaceuticals: Ramipril
  - Paul Miner and Lonnie Joe, Novartis: Lotrel
  - Jennifer Edsel, Alzheimer's Association, Forest: Namenda
  - Gary Ziegler, Schering-Plough: Foradil
  - Tom McMullen, Astra Zeneca: Crestor
  - Greg Warren, Wyeth: Effexor XR
  - Gregory Katz, M.D., St. Joseph's Hospital, Alcon: Vigamox
  - Steven Lasher, Genentech: Xolair
- IV. Approval of Minutes  
The minutes of the September 9<sup>th</sup> meeting were accepted as written.
- V. New Drug Reviews

Annette Paul provided a clinical overview of the new drugs for review.

The Committee made the following recommendations:

- Crestor  
Crestor should be added to the PDL without prior authorization (PA).  
A subgroup of the Committee shall meet to discuss the PDL sub-classification of "Statins for High Risk".
- Spectracef  
Spectracef should be added to the PDL, but will continue to require prior authorization.
- Vigamox  
Vigamox should be added to the Michigan Pharmaceutical Product List and receive coverage without restrictions.
- Zymar

Zymar should be added to the Michigan Pharmaceutical Product List and receive coverage without restrictions.

- Xolair

Xolair should be added to the Michigan Pharmaceutical Product List, but should continue to require prior authorization.

VI. Update from Previous Meeting

Dr. Perri reiterated the issues for consideration, namely:

1) Restasis (this product required PA prior to the December meeting):

In September, the Committee delayed the coverage recommendation for Restasis and opted to study prescribing activity before its next meeting. Dr. Perri noted that any anticipated, inappropriate prescribing for Restasis has not been documented.

Decision: The Committee adopted the recommendation to remove the PA requirement for Restasis.

2) Prevacid Solutab: (this product required PA prior to the December meeting):

In September, the Committee decided to delay its coverage recommendation pending investigation into the clinical advantages of this dosage form.

Decision: The Committee recommended to continue the PA requirements for Prevacid Solutab based upon the information presented. This is a form of Prevacid, already listed on the PDL under the trade name "Prevacid".

VII. Meeting Schedule for Calendar 2004

Dr. Johnson discussed and recommended the following dates for the 2004 Committee Schedule:

Tuesday, March 2, 2004

Tuesday, June 1, 2004

Tuesday, September 14, 2004

Tuesday, November 30, 2004

The Committee accepted the recommended 2004 Committee Schedule.

VIII. Adjournment

The meeting adjourned at 9:20 p.m.

**Next Meeting is Tuesday, March 2, 2004**

**6:00 P.M. – 9:00 P.M.**

**Kellogg Hotel and Conference Center**

**Respectfully submitted by Brad Sprecher**